JOURNAL OF PHARMA INSIGHTS AND RESEARCH ISSN NO. 3048-5428

REVIEW ARTICLE

Molecular Mechanisms of Clonal Hematopoiesis in Age-Related Cardiovascular Disease and Hematologic Malignancies

Lydia Amarachi Onwuemelem[*1], Enibokun Theresa Orobator[2], Nwamaka Nneka Onyedum[3], Eze Samson Chibueze[4], Ikechukwu Kanu[5], Adegbesan Abiodun Christopher[6], Olabisi Promise Lawal[7], Blessing Ben-Anioke[8]

[1] *Medical Laboratory Scientist, Medical Laboratory Science, University of Benin, Benin City, Edo State, Nigeria*
[2] *Medical Doctor, College of Medicine and Veterinary Medicine, Global Health and Infectious Diseases, University of Edinburgh, United Kingdom*
[3] *Resident Doctor, Haematology Department, Nnamdi Azikiwe University Teaching Hospital, Nnewi, Nigeria*
[4] *Research Scholar, Global Health and Infectious Disease Institute, Nasarawa State University, Keffi, Nigeria*
[5] *PG Scholar, Department of Chemistry, Ball State University, Muncie, Indiana, United States*
[6] *Research Scholar, African Cancer Institute, Department of Global Health, Stellenbosch University, Cape Town, SA*
[7] *Research Scholar, Department of Medical Laboratory Science, University of Benin, Benin City, Nigeria*
[8] *Research Scholar, Department of Hematology and Immunology, University of Nigeria Teaching Hospital, Enugu, Nigeria*

Publication history: Received on 8th Mar 2025; Revised on 21st March 2025; Accepted on 22nd March 2025

Article DOI: 10.69613/gexxbw35

Abstract: Clonal hematopoiesis (CH) serves as a molecular connection between aging and pathological conditions, particularly cardiovascular diseases and hematologic malignancies. Recent progress in genetic sequencing have identified somatic mutations in genes such as TET2, DNMT3A, and JAK2 that drive clonal expansion of hematopoietic stem cells, leading to various systemic effects. These mutations, often termed clonal hematopoiesis of indeterminate potential (CHIP), occur in approximately 10-20% of individuals over 70 years old and significantly impact cardiovascular health through enhanced inflammation and atherosclerosis. Additionally, CHIP mutations serve as precursors to hematologic malignancies, with annual progression rates of 1-2% to conditions such as acute myeloid leukemia and myelodysplastic syndromes. Large cohort studies and animal models have demonstrated that specific mutations in epigenetic regulators and signaling molecules contribute to both cardiovascular pathology and malignant transformation. The relationship between aging, CHIP mutations, and disease progression presents opportunities for novel therapeutic techniques, including targeted anti-inflammatory strategies and epigenetic modulators. These findings have significant implications for risk stratification and early intervention in aging populations, potentially revolutionizing preventive medicine approaches for age-related diseases. Integration of CH screening into clinical practice may enable personalized risk assessment and guide therapeutic decisions, though challenges remain in standardizing detection methods and determining optimal intervention techniques.

Keywords: Clonal hematopoiesis; Somatic mutations; Cardiovascular inflammation; Hematologic malignancies; Aging biomarkers.

1. Introduction

The emergence of clonal hematopoiesis (CH) as a central player in age-related diseases has revolutionized our perception of hematologic disorders and their systemic implications [1]. CH occurs when hematopoietic stem cells acquire somatic mutations, leading to the expansion of genetically distinct blood cell populations [2]. These mutations predominantly affect genes involved in epigenetic regulation, DNA repair mechanisms, and cellular differentiation pathways [3]. The clinical significance of CH extends beyond traditional hematologic boundaries, particularly in the context of clonal hematopoiesis of indeterminate potential (CHIP). CHIP is defined by the presence of somatic mutations in leukemia-associated genes at variant allele frequencies ≥2% in individuals without cytopenia or hematologic malignancies [4]. The age-dependent nature of these mutations has led to the parallel term age-related clonal hematopoiesis (ARCH), emphasizing its prevalence in older populations [5].

Recent genomic studies have identified key driver mutations in genes such as DNMT3A, TET2, and ASXL1, which play crucial roles in hematopoietic stem cell function and differentiation [6]. These mutations confer a selective advantage to affected cells, leading to their gradual expansion over time [7]. The consequent alterations in cellular function and inflammatory signaling create a permissive environment for both cardiovascular disease development and potential progression to hematologic malignancies [8].

* Corresponding author: Lydia Amarachi Onwuemelem

The identification of CH as a distinct entity emerged from large-scale genomic studies in the early 2010s [9]. Initial observations of unexplained skewing in X-chromosome inactivation patterns in elderly females provided the first hints of age-related clonal expansion in hematopoietic cells [10]. Subsequent technological advances in DNA sequencing enabled the detection of low-frequency somatic mutations, revealing the widespread nature of this phenomenon in aging populations [11]. The molecular foundations of CH rest on specific mutations that alter cellular function and behavior. These mutations typically affect three major cellular processes. Mutations in genes like DNMT3A and TET2 directly impact DNA methylation patterns, altering gene expression profiles and cellular identity [12]. These changes affect stem cell self-renewal and differentiation capabilities, potentially leading to aberrant hematopoiesis [13]. Alterations in signaling molecules, particularly JAK2 mutations, affect cellular response to growth factors and cytokines, influencing proliferation and survival pathways [14].



Figure 1. Evolution and Consequences of CH

Mutations in transcriptional regulators such as ASXL1 and TP53 modify gene expression patterns, affecting cell fate decisions and stress responses [15]. The clinical benefits of CH extend across multiple medical disciplines, affecting both hematologic and cardiovascular outcomes [16]. The presence of CHIP mutations correlates with increased mortality rates and serves as a potential biomarker for disease risk stratification [17]. Additionally, the identification of CH has opened new therapeutic possibilities, suggesting potential interventions to modify disease progression [18].

Table 1. Common Mutations Associated with Clonal Hematopoiesis

Gene	Frequency (%)	Common Functions	Associated Clinical Outcomes
DNMT3A	35-40%	DNA methylation	Increased cardiovascular risk
TET2	15-20%	DNA demethylation	Inflammation, atherosclerosis
ASXL1	10-15%	Chromatin modification	Poor prognosis in myeloid neoplasms
JAK2	8-12%	Signal transduction	Myeloproliferative disorders
TP53	5-7%	Tumor suppression	High risk of malignant transformation

2. Technical Methods in CH Research

2.1. Detection and Quantification Methods

Next-generation sequencing (NGS) technologies have revolutionized our approach to detecting and characterizing clonal hematopoiesis, establishing themselves as the cornerstone of modern detection strategies [19]. These sophisticated platforms have transformed our capability to identify subtle genetic variations, achieving remarkable sensitivity in detecting variant allele frequencies (VAF). While these technologies can identify mutations with VAFs as low as 0.1%, the clinical significance threshold typically begins at VAF ≥2% [20]. This enables researchers to detect early clonal events and track their evolution with precision, fundamentally changing our understanding of clonal dynamics in hematopoietic systems

2.1.1. Sequencing Methods

The spectrum of sequencing approaches in CH research encompasses multiple complementary strategies, each serving specific research objectives. Targeted panel sequencing has emerged as a primary tool for investigating recurrently mutated genes in CH, offering a focused and efficient approach to mutation detection. In contrast, whole-exome and whole-genome sequencing provide comprehensive mutation profiles, enabling the discovery of novel genetic alterations and complex genomic patterns [21]. Digital PCR and amplicon-based sequencing have established themselves as cost-effective alternatives for specific mutation detection, particularly valuable in clinical settings where targeted analysis of known mutations is required [22].

2.1.2. Bioinformatic Analysis

The computational analysis of CH-related sequencing data demands sophisticated bioinformatic approaches to ensure accurate interpretation. Advanced computational pipelines have been developed to address the unique challenges of somatic variant detection, incorporating multiple layers of filtering to distinguish genuine mutations from technical artifacts. These pipelines employ sophisticated algorithms to differentiate authentic somatic variants from germline polymorphisms [23]. The integration of machine learning algorithms has significantly enhanced mutation calling accuracy, particularly in challenging genomic regions. These computational tools have proven especially valuable in improving the detection of structural variants, which traditionally posed significant analytical challenges [24].

2.2. Study Design and Population Selection

Research into CH has utilized various study designs to establish its clinical significance:

2.2.1. Longitudinal Cohort Studies

Large-scale population studies have become instrumental in understanding the natural history and clinical implications of CH. These studies systematically track CH progression over extended periods, establishing crucial correlations between genetic alterations and various clinical outcomes [25]. The Framingham Heart Study, among other cardiovascular cohorts, has contributed significantly to our understanding of CH's role in cardiovascular disease development and progression. These longitudinal investigations have revealed complex relationships between clonal expansion patterns and adverse health outcomes [26].

2.2.2. Case-Control Studies

The implementation of comparative analyses between individuals with and without CH has proven invaluable in identifying risk factors and establishing disease associations [27]. These carefully designed studies frequently focus on specific age groups or disease conditions, allowing researchers to isolate and characterize CH effects with greater precision. This targeted approach has been particularly effective in elucidating the relationship between CH and various pathological conditions, while controlling for confounding variables [28].

2.3. Experimental Models

Laboratory investigations employ various models to describe CH mechanisms:

2.3.1. Animal Models

Genetically modified mouse models act as powerful tools for investigating the relationships between CH-associated mutations and disease phenotypes. These models enable researchers to establish direct causative relationships between specific genetic alterations and observed pathological changes [29]. Particularly noteworthy is their contribution to understanding the mechanistic links between CH and cardiovascular pathology. Through careful genetic manipulation and longitudinal observation, these models have revealed crucial insights into how CH-associated mutations influence inflammatory processes and vascular function. The ability to control genetic backgrounds and environmental conditions in these models has proven invaluable for understanding inter-relationship between clonal expansion and disease progression [30].

2.3.2. Cell Culture Systems

In vitro investigations utilizing primary human cells and established cell lines have provided fundamental insights into the molecular mechanisms underlying CH-associated mutations. These systems enable detailed examination of cellular behaviors, signaling pathways, and genetic interactions in controlled environments [31]. Recent advances in culture technology have led to the development of sophisticated systems that incorporate key components of the bone marrow niche, significantly improving the physiological relevance of in vitro studies. These advanced culture platforms better replicate the complex interactions between hematopoietic cells and their microenvironment, providing more accurate models for studying clonal evolution and cellular competition. The integration of three-dimensional culture systems and tissue-specific matrices has further enhanced our ability to model CH development and progression under conditions that more closely approximate the in vivo environment [32].

2.4. Quality Control

Rigorous quality control measures ensure reliable CH detection:

2.4.1. Technical Controls

Implementation of comprehensive technical control measures is crucial for validating the sensitivity and specificity of mutation detection methods. Sequential DNA dilutions serve as essential tools for establishing detection limits and ensuring consistent performance across different sample concentrations. Spike-in controls, incorporating known mutations at defined frequencies, provide crucial validation of mutation detection sensitivity [33]. Internal control systems have been developed to continuously

monitor sequencing quality and ensure accurate variant calling, incorporating multiple checkpoints throughout the analytical process. These controls enable researchers to identify and address technical variations that could impact results, maintaining high standards of data quality and reliability [34].

2.4.2. Clinical Validation

The establishment and maintenance of standardized protocols for sample collection, processing, and analysis represents a critical component of CH research quality control. These protocols ensure consistency and comparability of results across different laboratories and research institutions [35]. Regular participation in proficiency testing programs has become essential for maintaining high standards of mutation detection across institutions. These programs facilitate inter-laboratory comparisons and help identify areas requiring methodological refinement or additional standardization. Through systematic evaluation of testing procedures and results, these programs contribute to the continuous improvement of CH detection methods and ensure reliable identification of clinically significant mutations [36].

3. Clinical Hematopoiesis and the Aging Process

3.1. Age-Associated Prevalence

The relationship between clonal hematopoiesis and aging represents a fundamental aspect of human biology, with the frequency of CH showing a remarkable increase with advancing age. This association reflects intricate changes in hematopoietic stem cell (HSC) biology and the broader aging process [37]. Contemporary large-scale genomic studies have meticulously documented these age-related patterns, providing unprecedented insight into the temporal dynamics of clonal expansion and its relationship with human aging.

Table 2. Age-Related Prevalence of Clonal Hematopoiesis

Age Group	Prevalence (%)	Typical VAF Range	Risk of Progression/Year
<40 years	<1%	0.02-0.1	<0.1%
40-50 years	2-3%	0.02-0.1	~0.2%
50-60 years	5-10%	0.02-0.2	~0.5%
60-70 years	10-20%	0.02-0.3	~1%
>70 years	>20%	0.02-0.5	~1.5%

3.1.1. Age-Specific Distribution

The prevalence of CH demonstrates a distinct age-dependent pattern, with occurrence rates showing dramatic variation across different age groups. In individuals under 40 years, CH is relatively rare, affecting less than 1% of the population. However, this prevalence increases substantially with age, reaching 10-20% among individuals in their seventies and climbing to approximately 30% in octogenarians [38]. This exponential increase in prevalence suggests complex underlying mechanisms, including the progressive accumulation of molecular damage within hematopoietic stem cells and shifting selection pressures that favor certain mutations in the aging bone marrow environment. The consistent observation of this age-related pattern across multiple studies underscores its biological significance and suggests fundamental links between aging processes and clonal expansion [39]

3.1.2. Mutation Spectrum Evolution

The mutations associated with CH demonstrates distinct age-related patterns, reflecting the temporal dynamics of clonal evolution. DNMT3A mutations typically emerge as early events in the development of CH, suggesting their role as initiating mutations in clonal expansion. In contrast, mutations in genes such as PPM1D and TP53 tend to appear later in life, often in response to environmental stressors or therapeutic interventions [40]. This temporal hierarchy of mutations provides important insights into the mechanisms of clonal evolution and suggests potential windows for therapeutic intervention at different stages of the aging process.

3.2. Molecular Mechanisms of Age-Related CH

The emergence of CH in aging populations involves multiple cellular and molecular processes:

3.2.1. HSC Aging Characteristics

The aging of hematopoietic stem cells is characterized by multiple functional and molecular alterations that contribute to the development of CH. These aged HSCs demonstrate reduced self-renewal capacity, indicating compromised ability to maintain healthy hematopoiesis. Additionally, they exhibit a marked shift toward myeloid-biased differentiation, potentially contributing to the increased prevalence of myeloid disorders in older populations [41]. The emergence of enhanced inflammatory signaling in aged HSCs creates a microenvironment that favors the expansion of mutant clones, establishing a feed-forward loop that promotes clonal

dominance. These age-related changes collectively create a permissive environment that facilitates the expansion of mutant clones, contributing to the increased prevalence of CH in older populations [42].



Figure 2. Molecular Signaling Network in CH

3.2.2. DNA Damage Accumulation

The accumulation of DNA damage represents a critical mechanism underlying the development of CH in aging populations. This process is exacerbated by the progressive decline in DNA repair mechanisms that occurs with advancing age [43]. The combination of increased damage accumulation and reduced repair capacity creates conditions favorable for the acquisition of driver mutations. Furthermore, age-related increases in oxidative stress and progressive telomere attrition contribute to genomic instability, enhancing the likelihood of mutation acquisition and clonal expansion. These molecular changes create a genomic vulnerability that explains the increased prevalence of CH in aging populations [44].



Figure 3. Molecular Mechanisms and Interventions of CH

3.3. Impact on Aging Physiology

CH influences multiple aspects of aging biology:

3.3.1. Inflammatory Signaling

The relationship between CH-associated mutations and inflammatory signaling represents a crucial mechanism by which clonal hematopoiesis influences aging physiology. Mutations in key regulatory genes, particularly TET2 and DNMT3A, fundamentally alter the production and regulation of pro-inflammatory cytokines. This dysregulation contributes significantly to the development of chronic inflammation, a phenomenon often referred to as "inflammaging" [45]. The sustained inflammatory state generated by these mutations creates a self-perpetuating cycle that accelerates various age-related pathologies. This upregulated inflammatory signaling affects multiple organ systems, contributing to the development and progression of cardiovascular disease, metabolic dysfunction, and other age-associated conditions. The systemic nature of this inflammation helps explain the broad impact of CH on age-related health outcomes [46].

3.3.2. Stem Cell Competition

The competitive inhibition between mutant and normal hematopoietic stem cells in the aged bone marrow environment represent a fundamental aspect of CH biology. Mutant HSCs frequently demonstrate enhanced competitive advantages over their normal counterparts, particularly within the context of aged bone marrow environments [47]. This competitive advantage is further modulated by age-related changes in the bone marrow niche, including alterations in cytokine production, extracellular matrix composition, and cellular interactions. The complex interplay between mutant HSCs and the aging bone marrow microenvironment creates conditions that increasingly favor the expansion of mutant clones, contributing to the progressive nature of CH in aging populations [48].

3.4. CH as a Biomarker of Biological Age

The presence and extent of CH correlate with various aging parameters:

3.4.1. Clinical Correlation

The presence of clonal hematopoiesis has emerged as a powerful predictor of mortality risk, demonstrating significant associations independent of traditional cardiovascular and cancer risk factors [49]. The prognostic value of CH extends beyond its mere presence, with both the number of mutations and their variant allele frequencies providing additional layers of prognostic information. This quantitative relationship between CH characteristics and clinical outcomes underscores its utility as a biomarker of biological aging and suggests potential applications in risk assessment and clinical decision-making. The analysis of mutation patterns and clone sizes offers increasingly refined prognosis [50].

Table 3. Clinical Associations of Clonal Hematopoiesis

Clinical Condition	Relative Risk	Mechanisms
Cardiovascular Disease	1.8-2.5	Inflammation, IL-1β, IL-6
Hematologic Malignancies	11-13	Genomic instability
All-cause Mortality	1.4-1.7	Multiple pathways
Atherosclerosis	2.0-2.7	Enhanced inflammatory response
Type 2 Diabetes	1.3-1.6	Metabolic inflammation

3.4.2. Integration with Other Aging Markers

The significance of CH as a biomarker is further enhanced through its integration with other established markers of biological age. When combined with measurements of telomere length, DNA methylation age, and inflammatory markers, CH status provides complementary information about biological aging processes [51]. This multi-modal approach to assessing biological age offers more comprehensive insights into aging trajectories and associated health risks. The integration of multiple aging biomarkers, including CH status, has demonstrated improved capacity for risk stratification in aging populations, potentially enabling more personalized approaches to health monitoring and intervention strategies [52].

4. Clonal Hematopoiesis and Cardiovascular Disease

4.1. Mechanistic Links Between CH and Cardiovascular Pathology

CH mutations significantly influence cardiovascular disease (CVD) development through multiple pathways [53]:

4.1.1. Inflammatory Mechanisms

The impact of CH mutations on inflammatory processes represents a crucial mechanism linking clonal hematopoiesis to cardiovascular pathology. Macrophages bearing TET2 mutations demonstrate significantly enhanced pro-inflammatory responses, characterized by elevated production of key inflammatory mediators, particularly IL-1β and IL-6 [54]. This heightened inflammatory state creates a microenvironment conducive to accelerated atherosclerotic plaque formation and increased plaque instability, potentially precipitating acute cardiovascular events [55]. Similarly, mutations in DNMT3A exert profound effects on inflammatory signaling cascades, leading to widespread vascular dysfunction through altered endothelial cell function and enhanced inflammatory cell recruitment. These inflammatory perturbations contribute to a self-perpetuating cycle of vascular injury and inflammation [56].

4.1.2. Altered Lipid Metabolism

CH-associated mutations significantly impact cellular lipid handling mechanisms, particularly affecting macrophage function in atherosclerotic lesions. These mutations disrupt normal cholesterol efflux pathways and alter lipid metabolism within macrophages, promoting their transformation into foam cells - a critical step in atherosclerosis development [57]. The dysregulation of lipid handling mechanisms accelerates the development and progression of atherosclerotic lesions, creating more vulnerable plaques

prone to rupture. These metabolic alterations, combined with enhanced inflammatory responses, create a particularly aggressive form of atherosclerotic disease [58].

4.2. Clinical Manifestations of CH-Associated Cardiovascular Disease

Various cardiovascular conditions show strong associations with CH:

4.2.1. Atherosclerotic Disease

Individuals carrying CHIP mutations demonstrate significantly accelerated atherosclerosis progression and face an elevated risk of myocardial infarction compared to their non-CH counterparts [59]. The magnitude of this cardiovascular risk shows direct correlation with the variant allele frequency of the mutations and varies depending on the specific type of mutation present. This relationship suggests a dose-dependent effect of mutant clone size on cardiovascular pathology and highlights the importance of both quantitative and qualitative aspects of CH in disease progression [60].

4.2.2. Thrombotic Complications

The JAK2V617F mutation exhibits a particularly strong association with thrombotic events, affecting both the arterial and venous circulatory systems [61]. The prothrombotic state associated with this mutation stems from complex alterations in platelet function and endothelial cell activation. These changes create a hypercoagulable environment that significantly increases the risk of both spontaneous and provoked thrombotic events. The molecular mechanisms underlying this prothrombotic state involve multiple cellular components and signaling pathways [62].

4.3. Risk Stratification

The presence of CH influences cardiovascular risk assessment:

4.3.1. Predictive Value

The presence of clonal hematopoiesis serves as an independent predictor of adverse cardiovascular outcomes, providing additional prognostic information beyond traditional risk factors [63]. The predictive power of CH varies significantly based on both the type of mutation present and the size of the mutant clone, allowing for more nuanced risk assessment when these parameters are considered. This variability in predictive power shows the importance of comprehensive genetic analysis in risk stratification [64].

4.3.2. Interaction with Traditional Risk Factors

CH mutations demonstrate significant synergistic effects with conventional cardiovascular risk factors, including hypertension and diabetes [65]. This interaction suggests the need for modified approaches to risk assessment and management in individuals carrying CH mutations. The complex interplay between CH and traditional risk factors necessitates careful consideration in clinical decision-making and potentially indicates the need for more aggressive risk factor modification in affected individuals [66].

4.4. Therapeutic Implications for Cardiovascular Disease

Understanding CH-associated cardiovascular risk creates opportunities for targeted interventions:

4.4.1. Anti-inflammatory Approaches

The targeting of inflammatory pathways, particularly through IL-1β inhibition, has emerged as a promising therapeutic strategy for reducing cardiovascular events in individuals carrying CH mutations [67]. This approach directly addresses one of the primary mechanisms by which CH promotes cardiovascular pathology. Beyond IL-1β inhibition, researchers are actively investigating various other anti-inflammatory strategies designed to mitigate the downstream effects of CH mutations. These approaches include targeting alternative inflammatory mediators, modulating cellular stress responses, and addressing oxidative stress pathways that contribute to vascular dysfunction. The development of these targeted therapeutic methods represents a significant advance in the management of CH-associated cardiovascular risk [68].

4.4.2. Modified Risk Factor Management

The presence of CH mutations necessitates a reconsideration of traditional cardiovascular risk factor management approaches. Evidence suggests that more aggressive management of conventional risk factors may be warranted in individuals carrying CH mutations [69]. The development of tailored therapeutic approaches that consider specific mutation profiles offers the potential to optimize clinical outcomes through personalized intervention strategies. This individualized approach to risk factor management recognizes the heterogeneous nature of CH and its varying impacts on cardiovascular health, potentially leading to more effective prevention and treatment strategies [70].

5. Clonal Hematopoiesis and Hematologic Malignancies

5.1. Progression from CH to Hematologic Malignancies

The transformation from CH to hematologic malignancies involves stepwise genetic and epigenetic alterations [71]:

5.1.1. Genetic Evolution

The progression toward malignancy typically begins with driver mutations in epigenetic regulators, particularly DNMT3A and TET2, which establish a permissive cellular environment conducive to the acquisition of additional mutations [72]. This initial genetic disruption creates conditions favorable for the accumulation of secondary mutations in genes such as FLT3, NPM1, or NRAS, which ultimately drive the transformation to frank malignancy. The sequential acquisition of these mutations reflects a complex evolutionary process that underlies the progression from CH to hematologic malignancies [73].

5.1.2. Clonal Dynamics

The evolution of clonal populations follows distinct patterns, with certain mutations demonstrating greater potential for driving malignant transformation [74]. The rate at which secondary mutations are acquired varies significantly among different CH subtypes, reflecting the diverse biological consequences of different initiating mutations. This variation in clonal evolution patterns contributes to the heterogeneous nature of malignant transformation risks and trajectories observed in different CH subtypes [75].

5.2. Specific Malignant Transformations

CH predisposes to various hematologic malignancies:

5.2.1. Acute Myeloid Leukemia

The progression from CH to acute myeloid leukemia occurs at an annual rate of approximately 0.5-1%, representing a significant clinical concern [76]. The risk of transformation is particularly elevated in cases involving specific mutation combinations, notably those including TP53 or ASXL1 mutations. These high-risk genetic profiles require careful monitoring and may warrant more aggressive intervention strategies to prevent or delay malignant transformation [77].

5.2.2. Myelodysplastic Syndromes

The development of myelodysplastic syndromes frequently follows a period of detectable CH, with transformation rates showing significant variation depending on the specific mutation profile present [78]. Mutations affecting splicing factors, particularly SF3B1 and SRSF2, demonstrate especially strong associations with progression to MDS. The presence of these mutations often indicates a higher likelihood of MDS development and may influence monitoring and management strategies [79].

5.3. Risk Assessment and Monitoring

Effective surveillance strategies consider multiple factors:

5.3.1. Molecular Risk Stratification

The comprehensive evaluation of molecular characteristics plays a crucial role in predicting transformation risk in individuals with CH. This assessment encompasses multiple parameters, including the number of mutations present, their specific types, and their variant allele frequencies [80]. The dynamic nature of clonal evolution necessitates sequential monitoring of these molecular markers, providing crucial information that guides clinical management decisions. This longitudinal monitoring approach enables early detection of concerning changes in clonal architecture and allows for timely intervention when necessary. The integration of sophisticated molecular monitoring techniques has significantly enhanced our ability to track disease progression and adjust management strategies accordingly [81].

5.3.2. Clinical Risk Factors

The assessment of malignant transformation risk must consider various clinical factors that can significantly influence disease progression. Key considerations include patient age, the presence and severity of cytopenias, and any history of therapeutic exposures that might affect clonal evolution [82]. The integration of these clinical factors with molecular findings has substantially improved the accuracy of risk assessment, enabling more precise prediction of outcomes and better-informed clinical decision-making [83].

5.4. Therapeutic Considerations

Management strategies reflect evolving understanding of CH biology:

5.4.1. Preventive Approaches

The development of early intervention strategies for high-risk CH carriers represents a significant advance in disease management [84]. These approaches often involve the use of epigenetic modifiers, which show promise in preventing or delaying malignant transformation. The targeting of specific molecular pathways implicated in clonal evolution offers the potential to interrupt the progression toward malignancy, particularly in individuals identified as having high-risk molecular features. The implementation of these preventive strategies requires careful consideration of both the potential benefits and risks, balancing the goal of preventing malignant transformation against the potential side effects of intervention [85].

5.4.2. Treatment Modifications

The presence of CH significantly influences therapeutic decision-making in established malignancies [86]. Treatment strategies must be modified to account for the unique characteristics of CH-associated disease, as prior CH status can substantially affect both treatment response and long-term outcomes. This has led to more novel therapies, with treatment plans increasingly tailored to account for the specific molecular and clinical features of CH-associated disease [87].

Table 4. Current Monitoring and Management Strategies

Clinical Setting	Recommended Monitoring	Management Approach	Evidence Level
Incidental Finding	Annual CBC, mutation analysis	Observation	Moderate
Pre-transplant Donor	Molecular screening	Consider alternative donor	High
Cardiovascular Disease	Inflammatory markers, lipids	Intensive risk factor control	Moderate
Post-chemotherapy	Serial molecular testing	Modified treatment protocols	Limited
Age >70 with mutations	Biannual clinical assessment	Risk-adapted surveillance	Moderate

5.5. Impact on Stem Cell Transplantation

CH affects both donor selection and transplant outcomes:

5.5.1. Donor Considerations

The importance of screening potential donors for CH mutations has become increasingly apparent [88]. The age-related increase in CH prevalence poses particular challenges in donor selection, especially given the aging donor population. This demographic reality necessitates careful consideration of the potential risks and benefits associated with using donors who carry CH mutations. The development of screening protocols has become essential for optimizing donor selection and ensuring the best possible transplant outcomes [89].

5.5.2. Post-Transplant Outcomes

The presence of donor-derived CH has emerged as a significant factor influencing multiple aspects of transplant outcomes, including engraftment success, relapse risk, and overall survival [90]. This recognition has led to the development of more sophisticated monitoring strategies that must account for both recipient and donor CH status. The implementation of these monitoring approaches requires careful consideration of multiple factors, including the specific mutations present, their allele frequencies, and their potential interactions with other clinical variables. This monitoring enables early detection of potential complications and allows for timely intervention when necessary [91].

6. Therapeutic Approaches and Clinical Management

6.1. Current Therapeutic Strategies

The management of CH-associated conditions requires multifaceted approaches [92]:

6.1.1. Anti-inflammatory Interventions

The development of novel anti-inflammatory agents specifically targeting CH-mediated inflammation represents a significant advance in therapeutic strategy [93]. IL-1β inhibitors, particularly canakinumab, have demonstrated remarkable efficacy in reducing

cardiovascular events among individuals carrying CH mutations [94]. The therapeutic landscape continues to expand with the development of additional cytokine-targeted therapies focusing on IL-6 and TNF-α pathways. These interventions aim to disrupt the inflammatory cascade that contributes to disease progression, offering new possibilities for managing CH-associated complications [95].

6.1.2. Epigenetic Modulation

The application of DNA methyltransferase inhibitors and other epigenetic therapies presents a promising approach to influencing CH progression [96]. These therapeutic agents work by potentially restoring normal epigenetic patterns in mutant clones, addressing the fundamental molecular alterations that characterize CH. The ability to modify epigenetic programming offers unique opportunities for intervention at the earliest stages of disease development [97].

6.2. Risk-Adapted Prevention Strategies

Preventive measures vary based on individual risk profiles:

6.2.1. Cardiovascular Risk Management

The management of cardiovascular risk in CH carriers necessitates intensified prevention measures, including enhanced lipid management protocols that address the unique cardiovascular risks associated with CH [98]. Modified antiplatelet strategies accommodate the specific thrombotic risks present in CH carriers [99]. The integration of targeted anti-inflammatory approaches complements traditional cardiovascular risk management, creating comprehensive prevention strategies tailored to the unique pathophysiology of CH-associated cardiovascular disease [100]



Figure 4. Clinical Decision-Making Algorithm for CH management

6.2.2. Malignancy Prevention

The prevention of hematologic malignancy progression requires comprehensive strategies encompassing regular molecular monitoring to track disease evolution [101]. Early intervention in high-risk cases has become increasingly important as our understanding of risk factors improves [102]. The management of predisposing conditions plays a crucial role in preventing malignant transformation, requiring careful attention to factors that might accelerate disease progression [103].

6.3. Emerging Therapeutic Approaches

Novel therapeutic strategies target specific aspects of CH biology:

6.3.1. Targeted Molecular Therapies

The development of mutation-specific inhibitors represents a significant advance in addressing particular genetic alterations associated with CH [104]. Small molecule inhibitors targeting mutant proteins have shown considerable promise in preclinical studies, offering potential new therapeutic options for managing CH progression [105].

6.3.2. Immunological Approaches

The modulation of immune system function presents a promising approach to controlling CH clone expansion [106]. Novel immunotherapeutic strategies targeting CH-specific antigens offer potential new avenues for intervention, potentially enabling more precise control of pathogenic clonal populations [107].

6.4. Monitoring and Follow-up

Systematic monitoring protocols optimize patient care:

6.4.1. Molecular Monitoring

Sequential genetic analysis provides crucial information about clonal evolution patterns and disease progression [108]. The establishment of standardized monitoring intervals based on mutation profiles and risk factors enables more effective tracking of disease progression and response to intervention [109].

6.4.2. Clinical Surveillance

Regular assessment of organ system function plays a vital role in determining appropriate timing for therapeutic intervention [110]. The integration of molecular and clinical parameters in follow-up strategies enables more comprehensive patient monitoring, allowing for early detection of disease progression and optimization of therapeutic approaches [111].

7. Conclusion

The identification of CH as a critical link between aging, cardiovascular disease, and hematologic malignancies represents a significant advance in molecular medicine. This connection provides new opportunities for early intervention and disease prevention. The relationship between CH mutations and systemic disease progression necessitates multi-level collaboration to patient care. Future research will likely focus on personalized intervention based on specific mutation profiles and risk factors. The field of CH research exemplifies the potential of molecular medicine to bridge traditional medical specialties and improve patient outcomes. Success in this area may serve as a model for addressing other age-related diseases.

References

[1] Jaiswal S, Ebert BL. Clonal hematopoiesis in human aging and disease. Science. 2019;366(6465):eaan4673.

[2] Steensma DP, Bejar R, Jaiswal S, Lindsley RC, Sekeres MA, Hasserjian RP, et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood. 2015;126(1):9-16.

[3] Sperling AS, Gibson CJ, Ebert BL. The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia. Nat Rev Cancer. 2017;17(1):5-19.

[4] Genovese G, Kähler AK, Handsaker RE, Lindberg J, Rose SA, Bakhoum SF, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014;371(26):2477-87.

[5] Young AL, Challen GA, Birmann BM, Druley TE. Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults. Nat Commun. 2016;7:12484.

[6] Bowman RL, Busque L, Levine RL. Clonal hematopoiesis and evolution to hematopoietic malignancies. Cell Stem Cell. 2018;22(2):157-70.

[7] Fuster JJ, Walsh K. Somatic mutations and clonal hematopoiesis: unexpected potential new drivers of age-related cardiovascular disease. Circ Res. 2018;122(3):523-32.

[8] Jaiswal S, Natarajan P, Silver AJ, Gibson CJ, Bick AG, Shvartz E, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med. 2017;377(2):111-21.

[9] Busque L, Patel JP, Figueroa ME, Vasanthakumar A, Provost S, Hamilou Z, et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet. 2012;44(11):1179-81.

[10] Zink F, Stacey SN, Norddahl GL, Frigge ML, Magnusson OT, Jonsdottir I, et al. Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly. Blood. 2017;130(6):742-52.

[11] Bick AG, Weinstock JS, Nandakumar SK, Fulco CP, Bao EL, Zekavat SM, et al. Inherited causes of clonal haematopoiesis in 97,691 whole genomes. Nature. 2020;586(7831):763-8.

[12] Zhang X, Su J, Jeong M, Ko M, Huang Y, Park HJ, et al. DNMT3A and TET2 compete and cooperate to repress lineage-specific transcription factors in hematopoietic stem cells. Nat Genet. 2016;48(9):1014-23.

[13] Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Massé A, et al. Mutation in TET2 in myeloid cancers. N Engl J Med. 2009;360(22):2289-301.

[14] Vainchenker W, Kralovics R. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood. 2017;129(6):667-79.

[15] Abdel-Wahab O, Adli M, LaFave LM, Gao J, Hricik T, Shih AH, et al. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell. 2012;22(2):180-93.

[16] Dorsheimer L, Assmus B, Rasper T, Ortmann CA, Ecke A, Abou-El-Ardat K, et al. Association of mutations contributing to clonal hematopoiesis with prognosis in chronic ischemic heart failure. JAMA Cardiol. 2019;4(1):25-33.

[17] Bolton KL, Ptashkin RN, Gao T, Braunstein L, Devlin SM, Kelly D, et al. Cancer therapy shapes the fitness landscape of clonal hematopoiesis. Nat Genet. 2020;52(11):1219-26.

[18] Fuster JJ, MacLauchlan S, Zuriaga MA, Polackal MN, Ostriker AC, Chakraborty R, et al. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science. 2017;355(6327):842-7.

[19] Kennedy AL, Shimamura A. Genetic predisposition to MDS: clinical features and clonal evolution. Blood. 2019;133(10):1071-85.

[20] Desai P, Mencia-Trinchant N, Savenkov O, Simon MS, Cheang G, Lee S, et al. Somatic mutations predict acute myeloid leukemia years before diagnosis. Nat Med. 2018;24(7):1015-23.

[21] Abelson S, Collord G, Ng SWK, Weissbrod O, Mendelson Cohen N, Niemeyer E, et al. Prediction of acute myeloid leukaemia risk in healthy individuals. Nature. 2018;559(7714):400-4.

[22] Gibson CJ, Steensma DP. New insights from studies of clonal hematopoiesis. Clin Cancer Res. 2018;24(19):4633-42.

[23] Gao T, Ptashkin R, Bolton KL, Sirota M, Levine RL. Interplay between clonal hematopoiesis and aging in myeloid malignancies. Aging Cell. 2021;20(4):e13335.

[24] Zink F, Stacey SN, Norddahl GL, Frigge ML, Magnusson OT, Jonsdottir I, et al. Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly. Blood. 2017;130(6):742-52.

[25] Young AL, Tong RS, Birmann BM, Druley TE. Clonal hematopoiesis and risk of acute myeloid leukemia. Haematologica. 2019;104(12):2410-7.

[26] Jaiswal S, Libby P. Clonal haematopoiesis: connecting ageing and inflammation in cardiovascular disease. Nat Rev Cardiol. 2020;17(3):137-44.

[27] Bick AG, Pirruccello JP, Griffin GK, Gupta N, Gabriel S, Saleheen D, et al. Genetic interleukin 6 signaling deficiency attenuates cardiovascular risk in clonal hematopoiesis. Circulation. 2020;141(2):124-31.

[28] Cull AH, Snetsinger B, Buckstein R, Wells RA, Rauh MJ. Tet2 restrains inflammatory gene expression in macrophages. Exp Hematol. 2017;55:56-70.

[29] Sano S, Oshima K, Wang Y, MacLauchlan S, Katanasaka Y, Sano M, et al. Tet2-mediated clonal hematopoiesis accelerates heart failure through a mechanism involving the IL-1β/NLRP3 inflammasome. Nat Med. 2018;24(7):952-60.

[30] Dorsheimer L, Assmus B, Rasper T, Ortmann CA, Ecke A, Abou-El-Ardat K, et al. Association of mutations contributing to clonal hematopoiesis with prognosis in chronic ischemic heart failure. JAMA Cardiol. 2019;4(1):25-33.

[31] Coombs CC, Zehir A, Devlin SM, Kishtagari A, Syed A, Jonsson P, et al. Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes. Cell Stem Cell. 2017;21(3):374-82.

[32] Meisel M, Hinterleitner R, Pacis A, Chen L, Earley ZM, Mayassi T, et al. Microbial signals drive pre-leukaemic myeloproliferation in a Tet2-deficient host. Nature. 2018;557(7706):580-4.

[33] Yonal-Hindilerden I, Daglar-Aday A, Akadam-Teker B, Yilmaz C, Nalcaci M, Sargin D. Prognostic significance of ASXL1, JAK2V617F mutations and JAK2V617F allele burden in Philadelphia-negative myeloproliferative neoplasms. J Blood Med. 2015;6:157-75.

[34] Malcovati L, Gallì A, Travaglino E, Ambaglio I, Rizzo E, Molteni E, et al. Clinical significance of somatic mutation in unexplained blood cytopenia. Blood. 2017;129(25):3371-8.

[35] Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371(26):2488-98.

[36] Rauh MJ, Jacobsen E, Mills K, Ramasamy K. Molecular mechanisms of clonal hematopoiesis and its clinical implications. Blood Rev. 2020;42:100716.

[37] Libby P, Sidlow R, Lin AE, Gupta D, Jones LW, Moslehi J, et al. Clonal hematopoiesis: crossroads of aging, cardiovascular disease, and cancer: JACC review topic of the week. J Am Coll Cardiol. 2019;74(4):567-77.

[38] Steensma DP. Clinical consequences of clonal hematopoiesis of indeterminate potential. Blood Adv. 2018;2(22):3404-10.

[39] Silver AJ, Bick AG, Savona MR. Germline risk of clonal haematopoiesis. Nat Rev Genet. 2021;22(9):603-17.

[40] Zekavat SM, Lin SH, Bick AG, Liu A, Paruchuri K, Wang C, et al. Hematopoietic mosaic chromosomal alterations increase the risk for diverse types of infection. Nat Med. 2021;27(6):1012-24.

[41] Beerman I, Maloney WJ, Weissmann IL, Rossi DJ. Stem cells and the aging hematopoietic system. Curr Opin Immunol. 2010;22(4):500-6.

[42] Pang WW, Price EA, Sahoo D, Beerman I, Maloney WJ, Rossi DJ, et al. Human bone marrow hematopoietic stem cells are increased in frequency and myeloid-biased with age. Proc Natl Acad Sci USA. 2011;108(50):20012-7.

[43] Sudo K, Ema H, Morita Y, Nakauchi H. Age-associated characteristics of murine hematopoietic stem cells. J Exp Med. 2000;192(9):1273-80.

[44] Challen GA, Sun D, Jeong M, Luo M, Jelinek J, Berg JS, et al. Dnmt3a is essential for hematopoietic stem cell differentiation. Nat Genet. 2011;44(1):23-31.

[45] Sano S, Wang Y, Walsh K. Clonal hematopoiesis and its impact on cardiovascular disease. Circ J. 2019;83(1):2-11.

[46] Zhao LP, Gewirtz AM. Cardiovascular risk and clonal hematopoiesis: a new frontier. Curr Cardiol Rep. 2020;22(10):111.

[47] Busque L, Sun M, Buscarlet M, Ayachi S, Feroz Zada Y, Provost S, et al. High-sensitivity C-reactive protein is associated with clonal hematopoiesis of indeterminate potential. Blood Adv. 2020;4(11):2430-8.

[48] Bonnefond A, Skrobek B, Lobbens S, Eury E, Thuillier D, Cauchi S, et al. Association between large detectable clonal mosaicism and type 2 diabetes with vascular complications. Nat Genet. 2013;45(9):1040-3.

[49] Gibson CJ, Lindsley RC, Tchekmedyian V, Mar BG, Shi J, Jaiswal S, et al. Clonal hematopoiesis associated with adverse outcomes after autologous stem-cell transplantation for lymphoma. J Clin Oncol. 2017;35(14):1598-605.

[50] Cook EK, Luo M, Rauh MJ. Clonal hematopoiesis and inflammation: Partners in leukemogenesis and comorbidity. Exp Hematol. 2020;83:85-94.

[51] Robertson NA, Hillary RF, McCartney DL, Terradas-Terradas M, Higham J, Sproul D, et al. Age-related clonal haematopoiesis is associated with increased epigenetic age. Curr Biol. 2019;29(16):R786-7.

[52] Jaiswal S, Natarajan P. Clonal hematopoiesis: from mechanisms to clinical applications. Nat Med. 2022;28(2):235-44.

[53] Méndez-Ferrer S, Bonnet D, Steensma DP, Hasserjian RP, Ghobrial IM, Gribben JG, et al. Bone marrow niches in haematological malignancies. Nat Rev Cancer. 2020;20(5):285-98.

[54] Fuster JJ, MacLauchlan S, Zuriaga MA, Polackal MN, Ostriker AC, Chakraborty R, et al. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science. 2017;355(6327):842-7.

[55] Wang Y, Sano S, Yura Y, Ke Z, Sano M, Oshima K, et al. Tet2-mediated clonal hematopoiesis in nonconditioned mice accelerates age-associated cardiac dysfunction. JCI Insight. 2020;5(6):e135204.

[56] Cole CB, Russler-Germain DA, Ketkar S, Verdoni AM, Smith AM, Bangert CV, et al. Haploinsufficiency for DNA methyltransferase 3A predisposes hematopoietic cells to myeloid malignancies. J Clin Invest. 2017;127(10):3657-74.

[57] Yura Y, Sano S, Walsh K. Clonal hematopoiesis: a new step linking inflammation to heart failure. JACC Basic Transl Sci. 2020;5(2):196-207.

[58] Fidler TP, Xue C, Yalcinkaya M, Hardman B, Abramowicz S, Xiao T, et al. The AIM2 inflammasome exacerbates atherosclerosis in clonal haematopoiesis. Nature. 2021;592(7853):296-301.

[59] Bick AG, Weinstock JS, Nandakumar SK, Fulco CP, Bao EL, Zekavat SM, et al. Inherited causes of clonal haematopoiesis in 97,691 whole genomes. Nature. 2020;586(7831):763-8.

[60] Terao T, Kunisawa S, Shimizu T, Yamamoto Y, Sawa T, Yamazaki S, et al. Impact of clonal hematopoiesis on clinical outcomes after cardiovascular surgery. Circ J. 2021;85(7):1042-50.

[61] Wolach O, Sellar RS, Martinod K, Cherpokova D, McConkey M, Chappell RJ, et al. Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms. Sci Transl Med. 2018;10(436):eaan8292.

[62] Hinds DA, Barnholt KE, Mesa RA, Kiefer AK, Do CB, Eriksson N, et al. Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms. Blood. 2016;128(8):1121-8.

[63] Mas-Peiro S, Hoffmann J, Fichtlscherer S, Dorsheimer L, Rieger MA, Dimmeler S, et al. Clonal haematopoiesis in patients with degenerative aortic valve stenosis undergoing transcatheter aortic valve implantation. Eur Heart J. 2020;41(8):933-9.

[64] Genovese G, Jaiswal S, Ebert BL, McCarroll SA. Clonal hematopoiesis and blood-cancer risk. N Engl J Med. 2015;372(11):1071-2.

[65] Libby P, Ebert BL. CHIP (Clonal Hematopoiesis of Indeterminate Potential): potent and newly recognized contributor to cardiovascular risk. Circulation. 2018;138(7):666-8.

[66] Jaiswal S, Libby P. Clonal hematopoiesis: connecting aging and inflammation in cardiovascular disease. Nat Rev Cardiol. 2020;17(3):137-44.

[67] Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119-31.

[68] Sano S, Oshima K, Wang Y, Katanasaka Y, Sano M, Walsh K. CRISPR-mediated gene editing to assess the roles of Tet2 and Dnmt3a in clonal hematopoiesis and cardiovascular disease. Circ Res. 2018;123(3):335-41.

[69] Natarajan P, Jaiswal S, Kathiresan S. Clonal hematopoiesis: somatic mutations in blood cells and atherosclerosis. Circ Genom Precis Med. 2018;11(7):e001926.

[70] Calvillo-Argüelles O, Jaiswal S, Shlush LI, Moslehi JJ, Schimmer A, Barac A, et al. Connections between clonal hematopoiesis, cardiovascular disease, and cancer: a review. JAMA Cardiol. 2019;4(4):380-7.

[71] Bowman RL, Busque L, Levine RL. Clonal hematopoiesis and evolution to hematopoietic malignancies. Cell Stem Cell. 2018;22(2):157-70.

[72] Shlush LI, Zandi S, Mitchell A, Chen WC, Brandwein JM, Gupta V, et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature. 2014;506(7488):328-33.

[73] Welch JS, Ley TJ, Link DC, Miller CA, Larson DE, Koboldt DC, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell. 2012;150(2):264-78.

[74] Desai P, Mencia-Trinchant N, Savenkov O, Simon MS, Cheang G, Lee S, et al. Somatic mutations predict acute myeloid leukemia years before diagnosis. Nat Med. 2018;24(7):1015-23.

[75] Steensma DP. Clinical implications of clonal hematopoiesis. Mayo Clin Proc. 2018;93(8):1122-30.

[76] Yoshizato T, Dumitriu B, Hosokawa K, Makishima H, Yoshida K, Townsley D, et al. Somatic mutations and clonal hematopoiesis in aplastic anemia. N Engl J Med. 2015;373(1):35-47.

[77] Lindsley RC, Saber W, Mar BG, Redd R, Wang T, Haagenson MD, et al. Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation. N Engl J Med. 2017;376(6):536-47.

[78] Malcovati L, Galli A, Travaglino E, Ambaglio I, Rizzo E, Molteni E, et al. Clinical significance of somatic mutation in unexplained blood cytopenia. Blood. 2017;129(25):3371-8.

[79] Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van Loo P, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013;122(22):3616-27.

[80] Kennedy AL, Shimamura A. Genetic predisposition to MDS: clinical features and clonal evolution. Blood. 2019;133(10):1071-85.

[81] Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011;364(26):2496-506.

[82] Gibson CJ, Steensma DP. New insights from studies of clonal hematopoiesis. Clin Cancer Res. 2018;24(19):4633-42.

[83] Gondek LP, DeZern AE. Assessing clonal hematopoiesis: clinical implications and challenges. Curr Hematol Malig Rep. 2020;15(2):66-75.

[84] Jaiswal S, Ebert BL. Clonal hematopoiesis in human aging and disease. Science. 2019;366(6465):eaan4673.

[85] Steensma DP. Clinical consequences of clonal hematopoiesis of indeterminate potential. Blood Adv. 2018;2(22):3404-10.

[86] Sperling AS, Gibson CJ, Ebert BL. The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia. Nat Rev Cancer. 2017;17(1):5-19.

[87] Heuser M, Thol F, Ganser A. Clonal hematopoiesis of indeterminate potential. Dtsch Arztebl Int. 2016;113(37):629-34.

[88] Shaw BE, Hearps M, Guglielmelli P, Gerrits A, Berger G, Vannucchi AM, et al. Implications of donor clonal hematopoiesis in allogeneic hematopoietic stem-cell transplantation. J Clin Oncol. 2020;38(24):2798-810.

[89] Frick M, Chan W, Arends CM, Hablesreiter R, Halik A, Heuser M, et al. Role of donor clonal hematopoiesis in allogeneic hematopoietic stem-cell transplantation. J Clin Oncol. 2019;37(5):375-85.

[90] Gondek LP, Zheng G, Ghiaur G, DeZern AE, DeKelver RC, Blumberg N, et al. Donor cell leukemia arising from clonal hematopoiesis after bone marrow transplantation. Leukemia. 2016;30(9):1916-20

[91] Boettcher S, Miller PG, Sharma R, McConkey M, Leventhal M, Krivtsov AV, et al. A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies. Science. 2019;365(6453):599-604.

[92] Druley TE, Vallania FL, Wegner DJ, Varley KE, Knowles OL, Bonds JA, et al. Quantification of rare allelic variants from pooled genomic DNA. Nat Methods. 2009;6(4):263-5.

[93] Ridker PM, MacFadyen JG, Thuren T, Everett BM, Libby P, Glynn RJ, et al. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390(10105):1833-42.

[94] Libby P, Sidlow R, Lin AE, Gupta D, Jones LW, Moslehi J, et al. Clonal hematopoiesis: crossroads of aging, cardiovascular disease, and cancer. J Am Coll Cardiol. 2019;74(4):567-77.

[95] Chavakis T, Mitroulis I, Hajishengallis G. Hematopoietic progenitor cells as integrative hubs for adaptation to and fine-tuning of inflammation. Nat Immunol. 2019;20(7):802-11.

[96] Gardin C, Dombret H. Hypomethylating agents as a therapy for AML. Curr Hematol Malig Rep. 2017;12(1):1-10.

[97] Bejar R, Lord A, Stevenson K, Bar-Natan M, Pérez-Ladaga A, Zaneveld J, et al. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood. 2014;124(17):2705-12.

[98] Wang L, Zhang H, Rodriguez S, Cao L, Parish J, Mumaw C, et al. Notch-dependent repression of miR-155 in the bone marrow niche regulates hematopoiesis in an NF-κB-dependent manner. Cell Stem Cell. 2014;15(1):51-65.

[99] Koschmieder S, Chatain N. Role of inflammation in the biology of myeloproliferative neoplasms. Blood Rev. 2020;42:100711.

[100] Abegunde SO, Buckstein R, Wells RA, Rauh MJ. An inflammatory environment: relationship between cytokine levels and clonal hematopoiesis in the elderly. Aging Cell. 2018;17(4):e12740.

[101] Jongen-Lavrencic M, Grob T, Hanekamp D, Kavelaars FG, Al Hinai A, Zeilemaker A, et al. Molecular minimal residual disease in acute myeloid leukemia. N Engl J Med. 2018;378(13):1189-99.

[102] Savona MR, Malcovati L, Komrokji R, Tiu RV, Mughal TI, Orazi A, et al. An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms. Blood. 2015;125(12):1857-65.

[103] Moran-Crusio K, Reavie L, Shih A, Abdel-Wahab O, Ndiaye-Lobry D, Lobry C, et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell. 2011;20(1):11-24.

[104] Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424-47.

[105] Kunimoto H, Nakajima H. Epigenetic dysregulation of hematopoietic stem cells and preleukemic state. Int J Hematol. 2017;106(1):34-44.

[106] Jaiswal S. Clonal hematopoiesis and nonhematologic disorders. Blood. 2020;136(14):1606-14.

[107] Young AL, Challen GA. Clonal hematopoiesis in focus. Exp Hematol. 2019;77:1-13.

[108] Arends CM, Galan-Sousa J, Hoyer K, Chan W, Jäger M, Yoshida K, et al. Hematopoietic lineage distribution and evolutionary dynamics of clonal hematopoiesis. Leukemia. 2018;32(9):1908-19.

[109] Valent P, Orazi A, Steensma DP, Ebert BL, Haase D, Malcovati L, et al. Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions. Oncotarget. 2017;8(43):73483-500.

[110] Steensma DP, Bejar R, Jaiswal S, Lindsley RC, Sekeres MA, Hasserjian RP, et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood. 2015;126(1):9-16.

[111] Dorsheimer L, Assmus B, Rasper T, Ortmann CA, Ecke A, Abou-El-Ardat K, et al. Association of mutations contributing to clonal hematopoiesis with prognosis in chronic ischemic heart failure. JAMA Cardiol. 2019;4(1):25-33.